Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults
Orkin, Chloe, Molina, Jean-Michel, Gallant, Joel, Negredo, Eugenia, Gathe, Joseph, Eron, Joseph, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Opsomer, MagdaVolume:
4
Language:
english
Journal:
Open Forum Infectious Diseases
DOI:
10.1093/ofid/ofx180.009
Date:
October, 2017
File:
PDF, 272 KB
english, 2017